These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

764 related items for PubMed ID: 29479739

  • 21. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
    You Tm, Lee KH, Lee SH, Park W.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
    [Abstract] [Full Text] [Related]

  • 22. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?
    Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E.
    Oral Dis; 2018 Mar; 24(1-2):238-242. PubMed ID: 29480596
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw.
    J Clin Densitom; 2017 Mar; 20(1):8-24. PubMed ID: 27956123
    [Abstract] [Full Text] [Related]

  • 26. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T.
    Biol Pharm Bull; 2015 Mar; 38(12):1850-5. PubMed ID: 26632176
    [Abstract] [Full Text] [Related]

  • 27. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
    Jung S, Kim J, Park JH, Kim KY, Kim HJ, Park W.
    Sci Rep; 2022 May 23; 12(1):8641. PubMed ID: 35606457
    [Abstract] [Full Text] [Related]

  • 28. Emerging antiresorptive medications and their potential implications for dental surgeries.
    Aminoshariae A, Donaldson M, Horan M, Mackey SA, Kulild JC, Baur D.
    J Am Dent Assoc; 2022 Jul 23; 153(7):649-658. PubMed ID: 35277242
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Denosumab: a case of MRONJ with resolution.
    Lyttle CV, Patterson H.
    Br Dent J; 2016 Jun 24; 220(12):623-5. PubMed ID: 27338901
    [Abstract] [Full Text] [Related]

  • 31. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M.
    Cancer Treat Rev; 2018 Sep 24; 69():177-187. PubMed ID: 30055439
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
    Hauer L, Jambura J, Hrusak D, Chalupova M, Posta P, Rusnak S, Vyskocil V.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar 24; 164(1):100-107. PubMed ID: 30647474
    [Abstract] [Full Text] [Related]

  • 34. Successful conservative treatment of jaw osteonecrosis caused by denosumab in patients with multiple bone metastasis.
    Ohga N, Sato J, Asaka T, Morimoto M, Yamazaki Y, Kitagawa Y.
    J Oral Sci; 2018 Mar 24; 60(1):159-162. PubMed ID: 29576576
    [Abstract] [Full Text] [Related]

  • 35. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M, Kuroshima S, Sawase T.
    Int J Implant Dent; 2021 May 14; 7(1):47. PubMed ID: 33987769
    [Abstract] [Full Text] [Related]

  • 36. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
    Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb 14; 127(2):117-135. PubMed ID: 30393090
    [Abstract] [Full Text] [Related]

  • 37. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, Ueda N, Iwata E, Nakahara H, Kobayashi M, Soutome S, Yamada SI, Tojyo I, Kojima Y, Umeda M, Fujita S, Kurita H, Shibuya Y, Kirita T, Komori T, Japanese Study Group of Co-operative Dentistry with Medicine (JCDM).
    Osteoporos Int; 2019 Jan 14; 30(1):231-239. PubMed ID: 30406309
    [Abstract] [Full Text] [Related]

  • 38. Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach.
    de Souza Póvoa RC, Marlierè DA, da Silveira HM, Pires FR.
    Spec Care Dentist; 2016 Jul 14; 36(4):231-6. PubMed ID: 26859582
    [Abstract] [Full Text] [Related]

  • 39. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T.
    Cancer Chemother Pharmacol; 2021 Jun 14; 87(6):871-877. PubMed ID: 33791853
    [Abstract] [Full Text] [Related]

  • 40. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
    Yuan A, Munz A, Reinert S, Hoefert S.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb 14; 129(2):133-140. PubMed ID: 31606424
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.